Cancers, Vol. 11, Pages 857: Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside

Cancers, Vol. 11, Pages 857: Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside Cancers doi: 10.3390/cancers11060857 Authors: Debora Basile Paola Di Nardo Carla Corvaja Silvio Ken Garattini Giacomo Pelizzari Camilla Lisanti Lucia Bortot Lucia Da Ros Michele Bartoletti Matteo Borghi Lorenzo Gerratana Davide Lombardi Fabio Puglisi Mucositis is one of the most common debilitating side effects related to chemotherapy (CT), radiation therapy (RT), targeted agents and immunotherapy. It is a complex process potentially involving any portion of the gastrointestinal tract and injuring the mucosa, leading to inflammatory or ulcerative lesions. Mechanisms and clinical presentation can differ according both to the anatomic site involved (oral or gastrointestinal) and the treatment received. Understanding the pathophysiology and management of mucosal injury as a secondary effect of anti-cancer treatment is an important area of clinical research. Prophylaxis, early diagnosis, and adequate management of complications are essential to increase therapeutic success and, thus, improve the survival outcomes of cancer patients. This review focuses on the pathobiology and management guidelines for mucositis, a secondary effect of old and new anti-cancer treatments, highlighting recent advances in prevention and discussing future research options.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research